Redesigning t-PA for improved thrombolytic therapy.

doi:10.1016/0167-7799(91)90030-l

Back to search

Article

Redesigning t-PA for improved thrombolytic therapy.

Trends in biotechnology - 1 Mar 1991

Robinson J H, Browne M J

Abstract excerpt

Attempts are being made to redesign the structure of tissue-type plasminogen activator (t-PA) in order to increase its plasma half-life, increase its fibrin affinity or decrease its rate of interaction with plasma inhibitors. The principal strategies employed so far have been to construct hybrid...

Topics

Amino Acids
Drug Design
Fibrin
Half-Life
Humans
Mutation
Tissue Plasminogen Activator

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.